AFRICAN STANDARD

be cited as African Standard

African Traditional Medicine — General requirements for the manufacturing process of herbal medicinal products



Reference No. DARS 2154:2024(E) ICS 19617

© ARSO 2024

Contents		
Foreword		iii
Introduction.		V
AFRICAN	STANDARD	1
1 Scope		1
2 Norma	tive references	1
3 Terms	and definitions	1 🔀
4 Assura	nce of manufacturing process	4
4 1 P	remises	4
411	General	
4.1.1	Storade areas	
4.1.2	Droduction areas	5
4.1.3	Sanitation	5
4.1. 1	ocumentation	5
4.2 0	Conoral	5 5
4.2.1	Senerifications for ATM remedies Starters	
4.2.2	inished African Traditional Medicinal products	0
4.3.2 F		
4.2.4 4.0.2 Drev		8
4.2.3 Pro		δ
4.3 P		9
4.3.1	General	9
4.3.2	ATM control manager	9
4.3.3	Training	10
4.3.4	Personnel hygiene	10
4.4 Chang	ge control	10
4.5 D	eviation control	10
4.6 S	elf-inspections	11
Annex A		12
(normative).	······	12
Manufacturi	ng control	12
Annex B	·····	14
(normative).		14
Quality cont	ol	14
Bibliography		16
stricansta	ndardforcom	
atte		

Foreword

The African Organization for Standardization (ARSO) is an African intergovernmental organization established by the United Nations Economic Commission for Africa (UNECA) and the Organization of African Unity (AU) in 1977. One of the fundamental mandates of ARSO is to develop and harmonize African Standards (ARS) for the purpose of enhancing Africa's internal trading capacity, increase Africa's product and service competitiveness globally and uplift the welfare of African communities. The work of preparing African Standards is normally carried out through ARSO technical committees. Each Member State interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, Regional Economic Communities (RECs), governmental and non-governmental organizations, in liaison with ARSO, also take part in the work.

ARSO Standards are drafted in accordance with the rules given in the ISO/IEC Directives, Part 2.

The main task of technical committees is to prepare ARSO Standards. Draft ARSO Standards adopted by the technical committees are circulated to the member bodies for voting. Publication as an ARSO Standard requires approval by at least 75 % of the member bodies casting a vote.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ARSO shall not be held responsible for identifying any or all such patent rights.

This African Standard was prepared by ARSO *Technical Committee* on African Traditional Medicine (ARSO/TC 82)

© African Organisation for Standardisation 2024 — All rights reserved*

ARSO Central Secretariat International House 3rd Floor P. O. Box 57363 — 00200 City Square NAIROBI, KENYA

Tel. +254-20-2224561, +254-20-3311641, +254-20-3311608

E-mail: arso@arso-oran.org Web: www.arso-oran.org

^{* © 2024} ARSO — All rights of exploitation reserved worldwide for African Member States' NSBs.

Copyright notice

This ARSO document is copyright-protected by ARSO. While the reproduction of this document by participants in the ARSO standards development process is permitted without prior permission from ARSO, neither this document nor any extract from it may be reproduced, stored or transmitted in any form for any other purpose without prior written permission from ARSO.

Requests for permission to reproduce this document for the purpose of selling it should be addressed as shown below or to ARSO's member body in the country of the requester:

ed as Africat © African Organisation for Standardisation 2024 — All rights reserved

ARSO Central Secretariat International House 3rd Floor P.O. Box 57363 - 00200 City Square NAIROBI, KENYA

Tel: +254-20-2224561, +254-20-3311641, +254-20-3311608

E-mail: arso@arso-oran.org Web: www.arso-oran.org

Reproduction for sales purposes may be subject to royalty payments or a licensing agreement. Violators may be prosecuted. orat African Standard for comments only

standari

Introduction

Herbal medicinal products used in African Traditional Medicine are manufactured from materials of natural origin, the quality of which is varied according to geographical, climatic and seasonal conditions. For quality assurance of final products, quality evaluation on starting materials for herbal medicinal products used in ATM is essential. On the other hand, it is also important to handle these natural materials appropriately and to control manufacturing processes for herbal medicinal products used in ATM.

andar The management of manufacturing processes under good manufacturing practice (GMP) is indispensable to ensure quality of medicinal products. International GMP was issued by World Health Organization (WHO) in 1967, and a number of regional and international GMPs have subsequently been established. Recently, Pharmaceutical Inspection Convention (PIC)/Pharmaceutical Inspection Cooperation Scheme (PIC/S) has been widely applied around the world. At present, two-thirds of the member bodies of ISO/TC 249 are affiliated with PIC/S and some other countries are waiting for review of their applications.

These general GMPs were extensively applied to different fields and complimented with special supplements for herbal medicines in some countries and organizations. However, these herbal GMPs are focusing on European herbal medicines, but not covering those in the East Asian regions such as China, Japan and Korea where traditional medicines are used.

The current herbal GMPs of WHO, EU or PIC/S are mainly based on single herbal products, and the products consisting of more than one herbs were stipulated as special cases. However, multi-herbal products are more common than single-herbal products in the East Asian regions. In addition, raw materials in herbal GMPs of WHO, EU or PIC/S are only exclusive for plant origin, while traditional medicines in East Asia also include animal and mineral materials. In order to use correct materials, it is important to identify the starting materials not only by physical/chemical examinations but also by perceptive identification by well-trained experts. However, the requirement for experts on natural materials are not described in these international herbal GMPs. For a better safety and quality control of ATM products, conventional GMPs for the manufacturing of herbal medicines are in need of improvement.

Therefore, based on International GMPs, this document specifies the general requirements for the manufacturing processes of herbal medicinal plants used in ATM.

Implementation of this document with conventional GMPs for general ATM products would make it possible for manufacturers to ensure the safety and quality of natural products used in ATM, and at the same time protect people in countries where such products are used from health hazards caused by s w. poor quality products as well as improve their health.

AFRICAN STANDARD

African Traditional Medicine — General requirements for the manufacturing process of herbal medicinal products

1 Scope

This document specifies the general requirements for manufacturing processes to ensure the quality of finished products used in African Traditional Medicine. This document covers premises, documentation, personnel, training, manufacturing control and quality control. This document applies to the manufacturing of herbal medicinal products used in and as ATM.

This document does not conflict with general pharmaceutical good manufacturing practices (GMPs).

This document applies to all materials of natural origin: medicinal plants, medicinal animals, medicinal minerals and ATM preparations.

2 Normative references

ISO 19617-2018: General requirements for the manufacturing process of herbal medicinal products .

3 Terms and definitions

For the purpose of this document, the following terms and definitions apply.

ISO and IEC maintain terminological databases for use in standardization at the following addresses:

- ISO Online browsing platform: available at: http://www.iso.org/obp

- IEC Electropedia: available at: http://www.electropedia.org/

NOTE: African Traditional Medicines include various types of items. The same material can be classified in different categories (e.g. a powdered plant material can be both a crude herbal drug and a crude herbal drug preparation or, in a packed form, an ATM product).

3.1

active ingredient

crude drug(s) or the raw materials preparation(s) of African Traditional Medicine(s)

[SOURCE: WHO guidelines on good manufacturing practices (GMP) for herbal medicines, modified]

3.2

marker substance

chemically defined constituent of a raw materials utilized for control purposes

Note 1 to entry: Marker substances contribute or not to the clinical efficacy. When they contribute to the clinical efficacy, however, evidence that they are solely responsible for the clinical efficacy can be available or not.

Note 2 to entry: Marker substances are generally employed when constituents of known therapeutic activity are not known or are not clearly identified, and are used to identify the raw materials or preparation or calculate their quantity in the finished product.

[SOURCE: WHO guidelines on good manufacturing practices (GMP) for herbal medicines, modified]

3.3

medicinal animal

animal (wild or bred) used for medicinal purposes

3.4

medicinal mineral

mineral used for medicinal purposes

3.5

medicinal plant

plant (wild or cultivated) used for medicinal purposes

Note 1 to entry: Medicinal plants include ATM materials which could be derived from lichen, algae, fungi or higher plants, such as leaves, flowers, fruit, fruiting bodies, seeds, stems, wood, bark, roots, rhizomes Standar or other parts, which are entire, fragmented or powdered.

[SOURCE: WHO guidelines on good manufacturing practices (GMP) for herbal medicines, modified]

3.6

bulk product

product that has completed all processing stages up to, but not including, final packaging

3.7

raw material

medicinal part obtained from plants or animals, cell inclusions and secretions separated from the origins, their extracts, and minerals

Note 1 to entry: Herbal materials include, in addition to medicinal parts, fresh juices, gums, fixed oils, essential oils, resins and dry powders of herbs.

Note 2 to entry: In some countries, these materials are processed by various local procedures, such as steaming, roasting or stir-baking with honey, alcoholic beverages or other materials.

3.8

extract

preparation of liquid (liquid extracts and tinctures), semi-solid (soft extracts and oleoresins) or solid (dry extracts) consistency, obtained from medicinal plants, animals and minerals

3.9

finished product

finished dosage form or formulation that has undergone all stages of manufacture, including packaging in its final container and labelling

3.10

finished African traditional medicinal product

product consisting of ATM preparations made from one or more ATM raw materials

Note 1 to entry: If more than one raw material is used, the term "mixture ATM product" can also be used.

Note 2 to entry: Finished African Traditional Medicinal products and mixture ATM products contain excipients in addition to the active ingredients. However, finished African Traditional Medicinal products or mixture ATM products to which chemically defined active substances have been added, including synthetic compounds and/or isolated constituents from ATM raw materials, are not considered to be ATM products.

3.11

comminution

Comminution is the action of reducing of solid materials from one average particle size to a smaller average particle size, by crushing, grinding, cutting, vibrating, or other processes

3.12

African Traditional Medicinal product

material or product intended for human or veterinary use presented in its finished dosage form or as a starting material for use in such a dosage form

3.13

starting material

substance of a defined quality used in the production of an ATM product, but excluding packaging materials

3.14

manufacture

operations of purchase and/or receipt of materials and products, production, quality control, release and storage of ATM products, and the related controls

3.15

manufacturer

company that carries out operations such as production, packaging, repackaging, labelling and relabelling of pharmaceuticals

3.16

blending

process of combining materials or different batches to produce a homogeneous intermediate or finished product

3.17

packaging

operations, including filling and labelling, that a bulk product has to undergo in order to become a finished product

Note 1 to entry: Filling of a sterile product under aseptic conditions or a product intended to be terminally sterilized would not normally be regarded as part of packaging.

3.18

production

operations involved in the preparation of an ATM product, from receipt of materials, through processing, packaging and repackaging, labelling and relabelling, to completion of the finished product

3.19

qualification

action of proving that any premises, systems and items of equipment work correctly and actually lead to the expected results

Note 1 to entry: The meaning of the word "validation" is sometimes extended to incorporate the concept of qualification.

3.20

quality assurance

concept covering all matters that individually or collectively influence the quality of a product

Note 1 to entry: It is the totality of the arrangements made with the object of ensuring that ATM products are of the quality required for their intended use. Quality assurance therefore incorporates GMP and other factors, including those outside the scope of this guide such as product design and development.

3.21

quarantine

physical or other effective means of isolation implemented while a decision is awaited on the release, rejection or reprocessing of starting or packaging materials, intermediates or bulk or finished products

3.22

specification

list of detailed requirements with which the products or materials used or obtained during manufacture have to conform

Note 1 to entry: They serve as a basis for quality evaluation.

3.23 validation

action of proving, in accordance with the principles of GMP, that any procedure, process, equipment, material, activity or system actually leads to the expected results

Note 1 to entry: See also qualification (3.21).

3.24

packaging material

material, including printed material, employed in the packaging of a pharmaceutical, but excluding any outer packaging used for transportation or shipment

Note 1 to entry: Packaging materials are referred to as primary or secondary according to whether or not they are intended to be in direct contact with the product.

3.25

contamination

undesired introduction of impurities of a chemical or microbiological nature, or of foreign matter, into or on to a starting material or intermediate during production, sampling, packaging or repackaging, storage or transport

3.26

cross-contamination

contamination of a starting material, intermediate product or finished product with another starting material or product during production

3.27

clean area

area with defined environmental control of particulate and microbial contamination, constructed and used in such a way as to reduce the introduction, generation, and retention of contaminants within the area

4 Assurance of manufacturing process

4.1 Premises

4.1.1 General

As a general principle, premises shall be designed, located, constructed, adapted and maintained to suit the operations according to GMP, as the premises could be potentially affected by degradation and infestation of certain pests and are sensitive to microbiological contamination, production, and particularly storage of ATM raw materials and ATM preparations.

4.1.2 Storage areas

- a) Storage areas shall be well organized and tidy. Special attention shall be paid to cleanliness and good maintenance. Any accidental spillage shall be cleaned up immediately using methods that minimize the risk of cross-contamination of other materials, and shall be reported.
- b) The areas shall be well labelled and ATM Raw materials stored in such a way as to avoid any risk of cross-contamination. An area shall be identified for the quarantine of all incoming raw materials.

NOTE 1 The set-up of storage areas depends on the type of ATM raw materials stored.

- c) Storage areas shall be laid out to permit effective and orderly segregation of the various categories of materials stored, and to allow rotation of stock. Different Raw materials shall be stored in separate areas.
- d) Duration of storage of any raw materials in unpacked form shall be kept to a minimum.

NOTE 2 Minimum duration of storage protect stored material, and reduce the risk of pest attacks.

e) Incoming raw materials shall be processed, unless specified otherwise, as soon as possible and shall be stored at appropriate temperature to prevent bacterial and fungal growth.

- f) Where materials are stored in bulk, to reduce the risk of mould formation or fermentation it is advisable to store them in aerated rooms or containers using natural or mechanical aeration and ventilation. These areas shall also be equipped in such a way as to protect against the entry of insects or animals, especially rodents. Effective measures shall be taken to limit the spread of animals and microorganisms brought in with the raw material and to prevent cross-contamination.
- g) Raw materials, even when stored in fibre drums, bags or boxes, shall be stored off the floor and suitably spaced to permit cleaning and inspection.
- h) Appropriate steps shall be taken to ensure that conditions of humidity and temperature or protection from light are provided, maintained, monitored and recorded.

NOTE 3 The storage of raw materials, extracts, tinctures and other preparations require special conditions of humidity and temperature or protection from light.

i) Raw materials shall be kept in a dry area protected from moisture and processed following the principle of "first in, first out" (FIFO).

4.1.3 Production areas

- a) Production areas shall comply with the general requirements of GMP.
- b) As a rule, campaign work in their processing is necessary.
- c) If feasible, the use of dedicated premises is encouraged.
- d) The special nature of the production of African Traditional Medicines requires that particular attention be given to processing products that generate dust.
- e) When heating or boiling of the materials is necessary, a suitable air exhaust mechanism shall be employed to prevent accumulation of fumes and vapours.
- f) Adequate precautions shall be taken during the sampling, weighing, mixing and processing of raw materials, e.g. by use of dust extraction and air-handling systems to achieve the desired differential pressure and net airflow.
 - NOTE Adequate precautions facilitate cleaning and avoid cross-contamination.

4.1.4 Sanitation

a) A high-standard sanitation and hygiene requirement during manufacture is necessary.

NOTE 1 Raw materials contain microbiological contaminants due to their natural origin. During harvesting and processing, African Traditional Medicinal products could be contaminated by microorganisms.

NOTE 2 High-standard sanitation and hygiene avoid alterations and reduce contamination.

- b) The water supply to the manufacturing unit shall be monitored and, if necessary, treated appropriately to ensure consistency of quality.
- c) The quality of water for manufacturing shall be drinking water grade or higher.
- d) Waste from the manufacturing unit shall be disposed of regularly so as to maintain a high standard of hygiene in the manufacturing area.
- e) Clearly marked waste-bins shall be available, emptied and cleaned as needed.

4.2 Documentation

4.2.1 General

The general principles for documentation shall comply with GMP.

The intended purpose for the specifications for ATM remedies starters, ATM preparations and finished African Traditional Medicinal products is to define the quality rather than establish full characterization and they shall focus on those characteristics found to be useful in order to ensure safety and efficacy.

Consistent quality for African Traditional Medicines (finished African Traditional Medicinal products) can only be assured if the starting preparations are defined in a rigorous and detailed manner. In some cases, more detailed information may be needed on aspects of collection or agricultural production.

For instance, the selection of seeds, conditions of cultivation and harvesting are important for reproducible quality of African Traditional Medicines. Their characterization (which also includes a detailed evaluation of the botanical and phytochemical aspects of the ATM raw materials, manufacture of the raw material preparation and the finished African Traditional Medicinal product) is therefore essential to allow the establishment of specifications which are both comprehensive and relevant.

Specifications for ATM products raw materials shall as far as possible include, as a minimum, information of the starter material, finished African Traditional Medicinal products, ATM preparations, and processing instructions as described in the following clauses.

4.2.2 Specifications for ATM remedies Starters

- 1. The family and scientific name of the plant and animal shall be used according to the binomial system (genus, species, variety and the authority, i.e. the reference to the originator of the classification, e.g. *Linnaeus*).
- 2. The name of mineral shall be used according to the nomenclature of mineral standardized by the International Mineralogical Association (IMA).
- 3. Details of following items shall be included:
- a) the source of the plant and animal, such as country and/or region (also state and province, if applicable) of origin, whether it was cultivated or collected from the wild;
- b) where applicable, method of cultivation;
- c) dates and conditions of harvesting (e.g. whether there was extreme weather);
- d) collection procedures
- e) collection area;
- f) brand, quantity and date of pesticide application, as required by the GACP of domestic and/or international regulations.

The following specifications for starting materials (and also of primary or printed packaging materials) shall be included, if applicable, reference to a pharmacopoeia monograph:

- a) whether the whole plant or only a part is used;
- b) NOTE 1 In the latter case, which part of the plant is used and its state, e.g. whole or reduced.
- c) for dried plant material, the drying system, if applicable;

- d) a description of the plant material based on visual (macroscopic) and/or microscopic examination;
- e) suitable identity tests including, where appropriate, identification tests (such as TLC or other chromatographic fingerprint) for known active ingredients or marker substances;
- f) NOTE 2 A reference sample is available for identification purposes.
- g) details of the assay, where appropriate, of active constituents or marker substances;
- result of limit tests such as dry residue of liquids, ash value (total ash, and ash insoluble in hydrochloric acid), water-soluble extractives, moisture/water content and loss on drying (taking into account the presence of essential oils if any);
- result of suitable methods for the determination of possible pesticide contamination and the acceptable limits for such contamination in ATM raw materials or raw material preparations used in the manufacture of African Traditional Medicines;
- j) result of tests for toxic metals and for likely contaminants, foreign materials and adulterants;
- k) result of tests for fungal and/or microbiological contamination, fumigant residues (if applicable), mycotoxins, pest-infestations, radioactivity and their acceptable limits;
- result of other appropriate tests (e.g. particle size, swelling index and residual solvents in raw material preparations and biological fingerprints such as induced fluorescent marker substances).

4.3.2 Finished African Traditional Medicinal products

- 1. The control tests and specifications for the finished African Traditional Medicinal product shall be such as to allow the qualitative and quantitative determination of the main active constituents.
- a) If the therapeutic activity of constituents is known, these constituents shall be indicated in the documentation.
- b) If such substances are not known (e.g. because they are part of a complex mixture), the constituents useful for assessing the quality shall be identified as marker substances or fingerprints.
- c) In both cases, the assay (i.e. quantitative determination) specifications shall be defined.
- d) When the therapeutic activity of the constituents cannot be determined quantitatively, specifications shall be based on the determination of marker substances or fingerprints.
- 2. If either the final product or the raw material preparation contains several raw materials and a quantitative determination of each active ingredient is not feasible, the mixture of several active ingredients may be determined. The need for such a procedure shall be justified.
- 3. The concept of different acceptance criteria for release versus shelf-life specifications applies to finished African Traditional Medicines only but not to raw materials and raw material preparations.

Adequate retest periods shall be established for the latter. Examples where this may be applicable include assay and impurity (degradation product) levels:

- a. tests for microbiological contamination and tests for other toxicants;
- b. uniformity of weight (e.g. for tablets, single-dose powders, suppositories, capsules and herbal tea in sachets), disintegration time (for tablets, capsules, suppositories and pills), hardness and friability (for example, uncoated tablets), viscosity (for internal and external fluids), consistency (semisolid preparations), and dissolution (tablets or capsules), if applicable;
- c. physical appearance such as colour, odour, form, shape, size and texture;
- d. loss on drying, or water content;
- e. identity tests, qualitative determination of relevant substances of the raw materials (e.g. fingerprint chromatograms);
- f. quantification of relevant active ingredients, if they have been identified, and the analytical methods that are available;
- g. limit tests for residual solvents.

4.2.4 ATM preparations

The specifications of ATM preparations consist, depending on the preparation in question, of the relevant items of the specifications for the starters or for finished African Traditional Medicinal products as outlined above.

4.2.3 Processing instructions

- 1. The processing instructions shall include the following items:
 - a. descriptions of the different operations to be performed on the raw material, such as drying, crushing, milling and sifting;
 - b. the time and, if applicable, temperatures required in the drying process;

c. the methods to be used to control fragment or particle size;

d. instructions on removing foreign matter and other unwanted materials.

The drying conditions chosen shall be appropriate to the type of ATM product processed.

NOTE 1 The drying conditions depend on both the character of the active ingredients (e.g. essential oils) and the type of plant part collected (e.g. root, leaf or flower).

NOTE 2 Drying by direct exposure to sunlight, if not specifically contraindicated, is permitted, but drying on the ground is avoided.

NOTE 3 If the plant is processed fresh, without drying, the reasons and criteria determining the use of fresh material is stated.

- 3. For the production of processed extracts, the instructions shall specify details of any vehicle or solvent that may be used, the durations and temperatures needed for extraction, and any concentration stages and methods that may be required.
- 4. General instructions of manufacturing procedures to specify the manufacturing scale shall include the following items:
 - a. input order of starters;
 - b. solvent ratio and solvents;
 - c. rate of temperature increase;
 - d. extraction temperature;
 - e. extraction time;
 - f. number of extraction;
 - g. methods for solid-liquid separation;
 - h. methods for concentration;
 - i. methods for drying;
 - j. details of other special methods, if applicable;
 - k. yield and percentage yield in each manufacturing process;
 - I. Drug extract ratio.

NOTE 4 Standard ranges of yield and percentage yield are determined, taking into consideration raw material, manufacturing scale and other factors.

4.3 Personnel

4.3.1 General

General guidance in relation to personnel involved in the manufacture of medicinal products is given in the GMP of domestic and/or international regulations.

4.3.2 ATM control manager

4.3.2.1 General

Each manufacturing site dealing with ATM Products (whole, cut and powdered), bulk extracts, raw materials as finished products and African Traditional Medicinal products, shall assign qualified persons in charge of the management of raw materials in a quality division.

4.3.2.2 Competence of ATM control manager

The ATM control manager shall have expertise in ATM and be able to discriminate and handle ATM raw materials and products and analyse them.

4.3.2.3 Duties of ATM control manager

- 1. The ATM control manager shall have responsibility for the following and, if necessary, have the designated persons perform duties to control practically the matters concerning quality assurance of raw materials:
 - a. raw materials for ATM preparations;
 - b. source of supply, etc. of raw materials for African Traditional Medicinal products;

- c. methods to collect samples from ATM materials;
- d. evaluation of authentication results (including morphological quality) among tests and examinations on ATM raw materials;
- e. education and training for persons in charge of handling ATM materials;
- f. other duties on quality assurance for ATM materials.
- 2. The release of African Traditional Medicines shall be authorized by a person who has been trained in the specific features of the processing and quality control of raw materials, raw material preparations and finished African Traditional Medicinal products.
- 3. Personnel dealing with the production and quality control of African Traditional Medicines shall have adequate training in the specific issues relevant to African Traditional Medicines and analysis.

4.3.3 Training

- a) The personnel shall have adequate training in ATM handling and processing?
- b) Training records shall be maintained and periodic assessments of the effectiveness of training programmes shall be made.

4.3.4 Personnel hygiene

- a) Personnel entrusted with the handling of ATM raw materials, preparations and finished African Traditional Medicinal products shall be required to have a high degree of personal hygiene and to have received adequate training in maintaining appropriate standards of hygiene.
- b) The personnel shall not be on duty if they have infectious diseases or skin diseases.
- c) Written procedures listing the basic hygiene requirements shall be made available.
- d) Personnel shall be protected from contact with toxic irritants and potentially allergenic plant materials by means of adequate protective clothing.

4.4 Change control

- 1. In cases where any change will be made in the manufacturing procedure, etc. which could affect the quality of the products, the manufacturer shall designate beforehand a person to conduct the following duties in accordance with the documented procedure:
 - a. to evaluate the effects on the quality of the products due to such change;

to obtain approval from the manufacturing manager with respect to the change being made based on the results of the evaluation;

- c. to establish and maintain records of the evaluation and approval.
- 2. The manufacturer shall revise relevant documents, train the personnel and take other necessary actions in cases where any change is made upon approval of the manufacturing manager.

4.5 Deviation control

b.

a) In case any deviation from the manufacturing procedure, etc. has occurred, the manufacturer shall direct the person designated beforehand to evaluate effects on the quality of the products due to the deviation.

- b) The manufacturing manager shall permit the designated person to take proper actions based on the results of the evaluation.
- c) The manufacturer shall direct the designated person to establish and to maintain records of the evaluation in a CAPA (corrective action/preventive action) process.
- d) The manufacturer shall revise relevant documents, train personnel and take other necessary actions.

4.6 Self-inspections

The manufacturer/ Producer, etc. shall have the person designated beforehand to conduct the following duties:

- a. to conduct the self-inspections periodically on the manufacturing control (manufacturing control shall be in accordance with <u>Annex A</u>) and quality control (quality control shall be in accordance with <u>Annex B</u>) of the products in their manufacturing site, and to establish and maintain records of it;
- b. to report in writing the results of the self-inspections to the manufacturing manager;
- c. to take necessary action in cases where improvements are necessary, and to establish and maintain records of such actions.

Annex A (normative)

A. Manufacturing control A.1 General

To ensure not only the quality, but also the safety and efficacy of complex products of natural product origin such as African Traditional Medicines, it is essential that the steps in their production are clearly defined.

Collection/cultivation and/or harvesting of medicinal plants shall follow other relevant guidance such as GACP of domestic and/or international regulations.

Generally, postharvest processing including primary cutting is (or shall be) covered by GACP. If further comminutions is carried out in the manufacturing processing, it shall be covered by GMP, or by these supplementary guidelines. If cutting and comminution considerably reduce the probability of detection of adulteration or mix-up of raw materials, application of these supplementary guidelines may be extended to encompass these steps.

The manufacturing process shall be controlled particularly in relation to the prevention of contamination by microorganisms, based on the fact that raw materials and bulk extracts have nutrient-rich environments for microorganisms.

A.2 General considerations

Materials shall be handled in a fashion that is not detrimental to the product. On arrival at the processing facility, the raw material shall be promptly unloaded and unpacked. During this operation, the raw material shall not come into direct contact with the soil. Moreover, it shall not be exposed directly to the sun (except in cases where this is a specific requirement, e.g. sun-drying) and it shall be protected from rain and microbiological contamination.

Attention shall be paid to "classification" of clean area requirements taking into account the possible high degree of initial microbial contamination of raw materials. Classification of premises as applied to sites for the production of other pharmaceutical substances may not be applicable to processing of raw materials. Specific and detailed requirements shall be developed to cover microbial contamination of equipment, air, surfaces and personnel, and also for rest rooms, utilities, ancillary and supporting systems (e.g. water and compressed air).

Care shall be taken to choose cleaning methods appropriate to the characteristics of the raw materials being processed. Washing dried raw materials with water is generally inappropriate. When it is necessary to clean them, an air duster or air shower shall be employed. In cases when immersion of raw materials in water or other appropriate agents (such as disinfectants) for cleaning is unavoidable (e.g. to eliminate suspected coliform bacteria), it shall be kept to a minimum and documented.

The presence of plant materials from different species and varieties, or different plant parts shall be controlled during the entire production process to avoid contamination, unless it is assured that these materials are equivalent.

A.3 Mixing of batches and blending

ATM Materials with constituents of known therapeutic activity are often standardized (i.e. adjusted to a defined content of such constituents). The methods used to achieve such standardization shall be:

documented. Blending different batches of a specific ATM materials (e.g. before extraction) or by mixing different lots of similar ATM preparations may also be acceptable. Records shall be maintained to ensure traceability. The blending process shall be adequately controlled and documented and the blended batch shall be tested for conformity with established specifications where appropriate.

Batches shall be mixed only if it can be guaranteed that the mixture will be homogeneous. Such processes shall be well documented.

Out-of-specification batches of raw materials shall not be blended with other batches for the purpose of meeting specifications, except for standardization of the content of constituents with known pharmaceutical therapeutic effects. Every batch incorporated into the blend shall have been manufactured using an established process and shall have been individually tested and found to meet appropriate specifications prior to blending.

Where particular physical attributes of the material are critical, blending operations shall be validated to show uniformity of the combined batch. Validation shall include testing of critical attributes (e.g. particle size distribution, bulk density and tap density) that may be affected by the blending process.

The expiry date of the blended batch shall be chosen according to the date of manufacture of the oldest batch in the blend.

Annex B (normative)

B. Quality control

B.1 General

The personnel of quality control units shall have the necessary expertise in African Traditional Medicines to enable them to carry out identification tests and recognize adulteration, the presence of fungal growth or infestations and lack of uniformity in a consignment of raw materials.

The quality control of the raw material, raw material preparations and finished African Traditional Medicinal products shall establish their quality, but does not imply the control of every single constituent.

The personnel of quality control units shall collect samples necessary for testing from each lot of the products and to establish and maintain records of the collection and conduct the testing of the collected samples, for each lot or for each controlled unit, and to establish and maintain records of the testing.

B.2 Sampling

Because raw materials, an aggregate of individual plants and/or different parts of the same plant, may possess the heterogeneity, sampling shall be carried out with special care by personnel with the necessary expertise.

Further advice on sampling and visual inspection is given in pharmacopoeia and natural or international specifications.

B.3 Testing

The identity and quality of raw materials, raw material preparations and of finished African Traditional Medicinal products shall be tested appropriately (ISO 19609 will specify tests for technical equipment). Moreover, each country shall develop this basic requirement for technical equipment further, according to its own needs.

B.3.1 Classification

Raw material, raw material preparations (including extracts) and finished African Traditional Medicinal products can be categorized as follows:

- a) the active constituents are identified, and may be quantified as such;
- b) the main group of components which contribute to the activity (i.e. the constituents with known therapeutic activity) are known and can be quantified as a total (e.g. essential oils) or calculated using a representative substance belonging to the group (e.g. flavonoids);
- c) the formers are not identified and/or not quantifiable, but marker substances are presented;
- d) total fingerprints if marker substances are not useful;
- e) others, where quantification (i.e. specification for a certain quantity of a constituent) is not applicable or feasible.

B.3.2 Identification tests

Identification tests may be based on:

- physical and, if applicable, macroscopic (organoleptic) and microscopic tests;
- chromatographic procedures (TLC, HPLC, HPTLC or gas–liquid chromatography (GLC)), spectrometric techniques (ultraviolet-visible (UV-VIS), IR, nuclear magnetic resonance (NMR), Mass spectrometry); and/or chemical reactions.

The identification test methods shall be specified for the raw material, raw material preparation or finished African Traditional Medicinal product, and ideally shall be able to discriminate between the required herbal

material and potential substitutes or adulterants that are likely to occur. The identification methods used for groups a) and b) in $\underline{B.3.1}$ shall be able to detect the known active ingredients and at least the main ingredients shall be stated on the label. For group e), the analytical procedure shall be based on characteristic constituents, if any.

Reference samples of raw materials shall be made available for use in comparative tests, e.g. visual and microscopic examination and chromatography.

B.3.3 Quantitative determination

Quantitative determination of known active components for members of groups a) and b) in <u>B.3.1</u> and of marker substances for members of group c) is necessary.

The development and implementation of quality control methods for raw materials, raw material preparations and the finished African Traditional Medicinal products shall take into consideration the requirements of 4.2.

Particularly for herbal materials in group d) and for finished African Traditional Medicinal products containing such materials, characteristic chromatograms (and/or fingerprint chromatograms) may be applicable. Using these methods may ensure that the main constituents can be easily followed throughout the production process. Caution is necessary, however, for every delivery of raw materials and every batch of raw material preparations (including extracts) will have minor differences in chromatograms/fingerprints due to the differences in chemical compositions caused by intrinsic or extrinsic factors.

Bibliography

- [1] ISO 80000 (all parts), Quantities and units
- [2] ISO 128-30, Technical drawings General principles of presentation Part 30: Basic conventions for views
- [3] ISO 128-34, Technical drawings General principles of presentation Part 34: Views on mechanical engineering drawings
- [4] ISO 128-40, Technical drawings General principles of presentation Part 40: Basic conventions for cuts and sections
- [5] ISO 128-44, Technical drawings General principles of presentation Part 44: Sections on mechanical engineering drawings
- [6] ISO 690, Information and documentation Guidelines for bibliographic references and citations to information resources
- [7] ISO 10241-1, Terminological entries in standards Part 1: General requirements and examples of presentation
- [8] ISO 19609 (all parts)1), African Traditional Medicine Quality and safety of natural materials and manufacturing products made with natural materials used in and as African Traditional Medicine
- [9] IEC 60027 (all parts), Letter symbols to be used in electrical technology
- [10] ISO/IEC Directives: 2001, *Rules for the structure and drafting of International Standards*, Part 2
- [11] ISO/IEC/TR 10000-1, Information technology Framework and taxonomy of International Standardized Profiles Part 1: General principles and documentation framework
- [12] Australian regulatory guidelines for complementary medicines (ARGCM). In: Therapeutic Goods Administration, Canberra, Commonwealth of Australia, 2016
- [13] Good Manufacturing Practice and Quality Standards for Traditional Korean Medicine, 2008.ISO ab c:199x, General title of series of parts Part c: Title of part
- [14] Good Manufacturing Practice for Traditional Chinese Drugs, China, 2010
- [15] Guide to Good Manufacturing Practice for Medicinal Products. In: Therapeutic Goods Administration, Canberra, Commonwealth of Australia, 2009
- [16] Guide to good manufacturing practice for medicinal products, Geneva, Pharmaceutical Inspection Convention, Pharmaceutical Inspection Cooperation Scheme (PIC/S), 2013
- [17] Manufacture of Herbal Medicinal Products. In: Eudra Lex The Rules Governing Medicinal Products in the European Union, Volume 4, EU Guidelines to Good Manufacturing Practice, Medicinal Products for Human and Veterinary Use, Annex 7, European Commission, 2011
- [18] Manufacture of herbal medicinal products. In: Guide to good manufacturing practice for medicinal products, Annex 7, Geneva, Pharmaceutical Inspection Convention, Pharmaceutical Inspection Cooperation Scheme (PIC/S), 2013
- [19] Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Volume 2, In: Good manufacturing practices and Inspection, Second updated edition, Geneva, World Health Organization, 2007
- [20] Self-imposed Standards for Manufacturing and Quality Control of Crude drugs, Kampo Products and Crude Drug Products, the Federation of Pharmaceutical Manufacturers' Associations of Japan, Japan, 2012

Standard

- [21] The Rules Governing Medicinal Products in the European Union, Volume 4, EU Guidelines to Good Manufacturing Practice, Medicinal Products for Human and Veterinary Use, European Commission, 2011
- [22] WHO good manufacturing practices for pharmaceutical products: main principles. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations, Forty-fifth report, Annex 3 (WHO Technical Report Series, No. 961), Geneva, World Health Organization, 2011
- [23] WHO good manufacturing practices for pharmaceutical products: main principles. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations, Forty-eighth report, Annex 2 (WHO Technical Report Series, No. 986), Geneva, World Health Organization, 2014
- [24] WHO guidelines on good agricultural and collection practices (GACP) for medicinal plants, Geneva, World Health Organization, 2003
- [25] WHO guidelines on good manufacturing practices [GMP] for herbal medicines, World Health Organization, 2007

DARS 19617:2024